Welcome to our dedicated page for Tonix Pharmaceut news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceut stock.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) generates a steady flow of news as a fully integrated, commercial-stage biotechnology company with both marketed products and a broad development pipeline. News coverage for Tonix often centers on its FDA-approved fibromyalgia treatment TONMYA, its acute migraine products Zembrace SymTouch and Tosymra, and updates on clinical and regulatory milestones across central nervous system, immunology, rare disease and infectious disease programs.
Investors following TNXP news can expect announcements on commercial launches, market access decisions, and distribution arrangements for TONMYA, as well as prescription trends and formulary placements for its migraine therapies. The company also regularly reports progress on TNX-102 SL in indications such as acute stress-related conditions and major depressive disorder, including IND clearances and the design of potentially pivotal Phase 2 studies.
Tonix’s immunology and infectious disease work contributes additional news items, including collaborations with academic centers like Massachusetts General Hospital for TNX-1500 in kidney transplantation, and development plans for TNX-4800, a monoclonal antibody designed for seasonal prevention of Lyme disease. Licensing transactions, such as the acquisition of TNX-4900 for chronic neuropathic pain from Rutgers University, and government-supported projects like the DTRA-backed antiviral TNX-4200, are also common themes in company press releases.
This TNXP news page aggregates company-issued updates and related coverage so readers can quickly review developments in Tonix’s commercial operations, clinical pipeline, financing activities, and strategic collaborations. For investors and observers tracking biotech catalysts, revisiting this page provides a concise way to monitor how Tonix’s programs and capital markets actions evolve over time.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced its inclusion in the broad-market Russell 3000® Index and small-cap Russell 2000® Index, effective June 30, 2025. This addition comes as part of the 2025 Russell indexes reconstitution, which captures the 4,000 largest US stocks based on market capitalization rankings as of April 30.
The company is currently awaiting an FDA decision on TNX-102 SL for fibromyalgia management, with a PDUFA date of August 15, 2025. The FDA has granted Fast Track designation for this candidate. Additionally, Tonix has secured a contract worth up to $34 million over five years with the U.S. DoD's Defense Threat Reduction Agency for TNX-4200, a broad-spectrum antiviral agent.
Tonix's commercial subsidiary, Tonix Medicines, currently markets Zembrace® SymTouch® and Tosymra® for acute migraine treatment. The company's development portfolio includes various candidates targeting CNS disorders, immunology, and infectious diseases, with a state-of-the-art infectious disease research facility in Frederick, Md.
Tonix Pharmaceuticals presented promising preclinical data for gastric cancer treatment at the AACR 2025 Annual Meeting in Chicago. The research focused on a combination therapy using TFF2 with anti-PD1 antibody, showing positive results in activating cancer-killing CD8+ T cells.
The study demonstrated that TFF2-MSA, when combined with anti-PD1 antibody, effectively reduces immunosuppression in the tumor microenvironment. The company is developing TNX-1700 (TFF2-HAS) as their lead immuno-oncology program.
Key findings revealed that TFF2-MSA selectively reduces immunosuppressive neutrophils and cancer-driven granulopoiesis. The research also identified a potential negative correlation between TFF2 and PMN-MDSCs levels in gastric cancer patients, suggesting therapeutic potential for treating gastric and colorectal cancers.
Tonix Pharmaceuticals (TNXP) presented promising data for its TNX-801 mpox vaccine candidate at the World Vaccine Congress Washington 2025. The single-dose, live virus vaccine demonstrated protective immunity against mpox and smallpox in preclinical studies.
Key findings show that TNX-801:
- Protected immunocompromised animals from lethal clade IIa monkeypox virus challenge
- Provided six-month protection against lethal rabbitpox challenge
- Showed good tolerability in immunocompromised animals with no spreading to blood or tissues
- Prevented both clinical disease and lesion formation after single-dose vaccination
The vaccine development addresses ongoing concerns about mpox epidemics, with both clade IIb (2022) and clade Ib (2024) outbreaks being declared WHO Public Health Emergencies. TNX-801 aligns with WHO's preferred target product profile, featuring single-dose administration, durable protection, and ambient temperature stability.